PFE · 10-Q · 2026Q3 · Full report

Other Income and Impairments

PFIZER INC · 2026-11-03 · Importance 23 · Surprise 6 · In source text

Other income and deductions showed a favorable $229 million period-over-period change in the third quarter, reflecting the non-recurrence of a prior-year intangible impairment, lower legal charges, higher asset-disposal gains, and higher collaboration and out-licensing income. Those benefits were partly offset by net losses on equity securities versus prior-year gains and increased contingent-consideration liabilities. For the first nine months, the year-over-year change was unfavorable by $2.7 billion, driven by intangible impairment charges, contingent-consideration fair-value increases, and legal charges. A net gain from selling Pfizer’s previous ViiV investment partly offset the nine-month deterioration.

Key facts

• Pfizer recorded a $2.7 billion unfavorable period-over-period change in Other (income)/deductions—net for the first nine months of 2026, driven primarily by intangible-asset impairment charges, contingent-consideration fair-value increases, and legal charges. source

Impact estimates